Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Organic Process Research & Development

Investigation of Pd Catalyst for Key Coupling Reaction in Asciminib Synthesis and Impurity Characterization

View Full Paper
Ask AI
Bookmark
Share

Authors

KAKiran AluriHPHrithvik Reddy PullagurlaSASyam Prasad Reddy Annareddy

Discussion

Loading...

Member takes

Overview

Research reveals an optimized palladium catalyst enhances coupling reaction efficiency in asciminib synthesis, highlighting impurity management.

Key Points

  • Complete conversion of the desired coupling product achieved with a reduced palladium catalyst amount.
  • The use of dichlorobis[ditert-butyl(4-dimethylaminophenyl)phosphine]palladium(II) proved most effective in the coupling reaction.
  • Identification and synthesis of potential process and degradation impurities enhance the overall quality of asciminib.
  • Validation of the optimized production process was successfully completed under GMP conditions for scalability.

Cite This Study

Aluri et al. (2025) studied this question.

synapsesocial.com/papers/68dd91c7fe798ba2fc498437https://doi.org/10.1021/acs.oprd.5c00192
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Quantification of Asciminib and its impurities: A RP-UPLC study2024
  2. 2FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation2024 · 13 citations
  3. 3Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL12018 · 468 citations
  4. 4Development of asciminib, a novel allosteric inhibitor of BCR-ABL12022 · 59 citations
  5. 5Asciminib: a new therapeutic option in chronic-phase CML with treatment failure2022 · 47 citations